Kura Oncology (NASDAQ:KURA) Stock Rating Reaffirmed by HC Wainwright

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $32.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 82.75% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on KURA. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday. Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the company from $26.00 to $19.00 in a research note on Monday, October 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Monday, September 9th. JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.83.

Kura Oncology Stock Down 1.5 %

KURA stock opened at $17.51 on Thursday. Kura Oncology has a 52 week low of $7.52 and a 52 week high of $24.17. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The firm has a 50-day simple moving average of $19.34 and a 200-day simple moving average of $20.09. The stock has a market capitalization of $1.34 billion, a P/E ratio of -7.85 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.04. During the same period in the previous year, the company posted ($0.53) earnings per share. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. Equities analysts forecast that Kura Oncology will post -2.46 earnings per share for the current fiscal year.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in Kura Oncology in the third quarter valued at approximately $25,000. ProShare Advisors LLC lifted its stake in shares of Kura Oncology by 9.7% in the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after purchasing an additional 1,588 shares during the last quarter. Aaron Wealth Advisors LLC grew its holdings in shares of Kura Oncology by 2.4% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock worth $1,444,000 after purchasing an additional 1,673 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Kura Oncology by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares during the last quarter. Finally, Hsbc Holdings PLC raised its holdings in Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after buying an additional 2,167 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.